Australia, May 19 -- ACADIA Pharmaceuticals Inc., owns the trademark (2626903) for 'DAYBUE STIX' till Jan. 8, 2036.
Status: protected:
Registered/protected
Classes: 5 [Pharmaceutical preparations for the treatment and prevention of neurologic, genetic, psychologic, and psychiatric diseases and disorders.], 35 [Promoting awareness of patient support offerings for neurologic, genetic, psychologic, and psychiatric diseases and disorders; business administrative services for medical referrals.] and 44 [Consultancy in the field of the medical treatment of neurologic, genetic, psychologic, and psychiatric diseases and disorders, including Rett syndrome; consultancy in the field of the medical diagnosis of neurologic, genetic, psychologic, and psychiatric diseases and disorders, including Rett syndrome; health care services, namely, providing online information for health care providers, caregivers, and patients in the field of neurologic, genetic, psychologic, and psychiatric diseases and disorders; health care services, namely, providing information about the benefits of diagnostic tools, medical information regarding disease diagnosis, identification, treatment, and management, and healthcare-related information to patients, caregivers, and healthcare professionals all related to neurologic, genetic, psychologic, and psychiatric diseases and disorders.]
Type of Mark: Word
Date of Acceptance: March 10
Registration Advertised: May 18
For further details contact PLLC Carissa L. Weiss Law Office of Carissa L. Weiss.
The original document can be viewed at: https://search.ipaustralia.gov.au/trademarks/search/view/2626903.
Disclaimer: Curated by HT Syndication.
